Recent Updates
Recently added Catalysts
INSM Positive Sentiment

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: Insmed Incorporated announced it will release its second-quarter 2023 financial results on August 3, 2023. Management will host a conference call for investors at 8:30 a.m. ET to discuss these results and provide a business update. Shareholders can participate in the call by phone or via a live web broadcast on the company's website. Insmed is known for its innovative therapies in serious and rare diseases, indicating a focus on advancing healthcare solutions.
Price reaction · baseline $21.11 (2023-07-19 close) · hit after-hours · clean, no other INSM news in the window
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is progressing new investigational therapies targeting serious unmet medical needs.
  • The company is hosting a conference call to transparently discuss financial results and business updates.
  • Insmed has a first-in-disease therapy that is approved in multiple major markets.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.7%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
Brensocatib
Phase 3 · Non-Cystic Fibrosis Bronchiectasis

Full Press Release Details

BRIDGEWATER, N.J. , July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2023 financial results on Thursday, August 3, 2023 .
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 3, 2023 , to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (646) 960-0278 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the company's website at www.insmed.com .
A replay of the conference call will be accessible approximately 1 hour after its completion through September 3, 2023 , by dialing (647) 362-9199 (U.S. and international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com .
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .

Frequently Asked Questions

When will Insmed release its Q2 2023 financial results?

Insmed will release its second-quarter 2023 financial results on August 3, 2023.

What time is the conference call for Q2 results?

The conference call will begin at 8:30 a.m. ET on August 3, 2023.

How can I participate in the Insmed conference call?

Participants can dial (646) 960-0278 and use access code 7862189.

Is there a webcast of the conference call?

Yes, the call will be webcast live on Insmed’s website.

How long will the conference call replay be available?

The replay will be available until September 3, 2023.

Last updated: Jul 20, 2023